Skip to content. | Skip to navigation

Personal tools
Sections
You are here: Home Breaking news EU proposes ban on new psychoactive substance

EU proposes ban on new psychoactive substance

— filed under: , , ,
EU proposes ban on new psychoactive substance

Photo United Nations office on Drugs and Crime

(BRUSSELS) - The European Commission proposed Wednesday to subject the new psychoactive substance MDMB-CHMICA, sometimes referred to as 'Black Mamba', to control measures across the European Union.

According to a risk assessment report from by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), the acute toxicity of MDMB-CHMICA can cause severe harm to the health of individuals.

28 deaths and 25 acute intoxications associated with MDMB-CHMICA have so far beenb reported in eught EU Member States. Multiple reports have also indicated the possibility that its use causes violence and aggression.

Swifter and more effective EU action in the fight against new psychoactive substances was also promised by the EU Commission this week as it proposed an amendment to the founding Regulation of the EMCDDA.

The proposal aims to strengthen the EU early warning system and risk assessment on new psychoactive substances by streamlining and speeding up data collection and assessment procedures. The approach was agreed with the European Parliament and the Council to advance the negotiations on the package of legislative proposals on NPS proposed in September 2013.

Home Affairs Commissioner Dimitris Avramopoulos said: "The number, type and availability of harmful new drugs continue to grow in Europe, and Member States cannot effectively fight the spread of these new psychoactive substances alone. Our proposal to subject MDMB-CHMICA or "Black Mamba" to control measures is part of our efforts to effectively address the threat posed by new psychoactive substances on a European level.

"The same is true for our proposal to strengthen the EU's early warning system and risk assessment - it will allow for a more systematic and sophisticated monitoring and swifter decision-making on new psychoactive substances."

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)


Document Actions